OGT ads

Stop losing hours to library prep 🧪 OGT's Universal NGS Workflow Solution V2, optimised for SureSeq™ and CytoSure® panels, slashes hands-on time by: ☑️Combining steps: Fragmentation, end-repair, and A-tailing now happen in one multi-enzymatic step. ☑️ Reducing QC: Fewer cleanups mean better scalability and fewer chances for mistakes. ☑️Boosting Confidence: Integrated UDI/UMI adapters from the start for high-sensitivity applications. Hear from Sean Glenn, PhD - Roswell Park Cancer Institute – on this easy-to-use replicable library prep workflow. #SureSeq #MRD #MeasurableResidualDisease #NGS #Haematology #HemeOnc #Oncology #CancerResearch #PrecisionMedicine #LibraryPrep #OGT *For Research Use Only; Not for Use in Diagnostic Procedures

🕔Accelerate molecular insights: detect low-level MRD signals sooner with enhanced NGS sensitivity Harness the power of AML target coverage and ultra-sensitive variant detection with the SureSeq™ Myeloid MRD Plus NGS Panel*. Bring elusive variants to light sooner, providing earlier, data-rich insights into molecular dynamics. Learn about the power of ultra-sensitive variant detection from Sean Glenn, PhD - Roswell Park Cancer Institute - in a retrospective cohort study of research specimens collected from patients undergoing AML treatment. #SureSeq #MRD #MinimalResidualDisease #NGS #Haematology #HemeOnc #Oncology #CancerResearch #PrecisionMedicine *For Research Use Only; Not for Use in Diagnostic Procedures

Discover the new SureSeq™ Myeloid MRD Plus NGS Panel 🔬 Unlock actionable insights with a reliable, highly targeted panel for detection of 53 hotspot exons across 16 genes. Join “Harnessing NGS-based MRD detection: Insights from a retrospective AML cohort study” as Sean Glenn, PhD - Roswell Park Comprehensive Cancer Center, shares his insights from a retrospective cohort study of research specimens collected from AML patients POS-HSCT. #SureSeq #MRD #MeasurableResidualDisease #NGS #Haematology #HemeOnc #Oncology #CancerResearch #PrecisionMedicine #OGT *For Research Use Only; Not for Use in Diagnostic Procedures

With ~20k new cases a year, AML is the most common acute leukaemia affecting adults. OGT’s new SureSeq™ Myeloid MRD Plus NGS Panel* allows you to: ☑️Detect a wide range of variants and structural aberrations with Interpret NGS analysis software ☑️ Customise reporting, including longitudinal visualisation, mutation tracking, and discovery mode ☑️ Save laboratory time and costs by reducing number of assays Join “Harnessing NGS-based MRD detection: Insights from a retrospective AML cohort study” as Sean Glenn, PhD - Roswell Park Comprehensive Cancer Center, expands on this targeted solution. #SureSeq #MRD #MeasurableResidualDisease #NGS #Haematology #HemeOnc #Oncology #CancerResearch #PrecisionMedicine #OGT *For Research Use Only; Not for Use in Diagnostic Procedures

In this white paper Kingston Health Sciences Centre detail their collaboration with OGT to develop a custom SureSeq myPanel™, designed to detect SNVs, indels, ITDs, PTDs and CNVs at both exon and whole-gene levels. Key outcomes from the study: 🧬 Comprehensive, efficient genomic insights generated in a single assay 🧬 OGT’s probe design optimisation significantly boosted target coverage 🧬 Robust analytical performance with 98% sensitivity and 100% specificity for SNV detection Download the white paper to view the detailed results. #myeloid #customNGS #myPanel #SureSeq #OGT SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures.

Enhance your MRD NGS capabilities with SureSeq™ With robust detection of complex and challenging mutations to achieve exceptional sensitivity, detecting variants at ultra-low frequencies, the SureSeq Myeloid MRD Plus NGS Panel* delivers comprehensive genomic insights from your AML samples. Unlock your MRD detection capabilities today: https://lnkd.in/eSHUWUpi #SureSeq #MRD *SureSeq: For Research Use Only; Not for Use in Diagnostic Procedures